Table 3.

Final parameter estimates and effect of genetic and clinical factors on tacrolimus CL/F

	Study population1		Bootstrap analysis2
Parameter	Estimate (%RSE)3	95% CI4	Median	2.5th–97.5th percentiles
Tacrolimus CL/F5	38.4 (4.14)	35.3, 41.5	38.3	35.5, 41.7
Factors affecting CL/F
6–10 DPT6	0.86 (4.13)	0.80, 0.93	0.86	0.80, 0.93
11–180 DPT6	0.71 (4.14)	0.66, 0.77	0.72	0.66, 0.77
CYP3A5*1/*3	1.70 (3.99)	1.56, 1.82	1.69	1.56, 1.82
CYP3A5*1/*1	2.00 (5.90)	1.77, 2.23	1.99	1.77, 2.23
Steroid sparing centre	0.70 (3.50)	0.65, 0.75	0.70	0.65, 0.75
(Age/50)θ	−0.40 (13.5)	−0.50, −0.30	−0.39	−0.50, −0.29
CCB use7	0.94 (2.43)	0.89, 0.98	0.94	0.90, 0.99
IIV8 for CL/F, %CV	40.1	37.4, 43.6	40.0	37.4, 43.6
RUV9, additive, SD	3.19	3.07, 3.32	3.19	3.08, 3.32

¹681 patients analysed in this study

²results from 989 bootstrap runs with successful convergence and successful covariance step

³per cent relative standard error

⁴confidence interval: estimate ± (1.96*standard error of estimate)

⁵typical value of CL/F in l h⁻¹

⁶days post transplant

⁷calcium channel blocker use at the time of trough measurement

⁸inter-individual variability

⁹random unexplained variability.